XORTX Therapeutics Stock Price

TSXV:XRTXCA$4.9mPharmaceuticals & Biotech

XRTX Share Price Performance

XRTX Community Fair Values

View all narratives

Recent XRTX News & Updates

No updates

XORTX Therapeutics Inc. Competitors

About XRTX

Founded: n/a
Employees: 3
CEO: Allen Davidoff
WebsiteView website: www.xortx.com

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment of type 2 diabetic nephropathy. It has a license agreement with the University of Florida Research Foundation, Inc. for the use of uric acid lowering agent to treat insulin resistance. The company is based in Calgary, Canada.

XORTX Therapeutics Inc. Key Details

Last Reported Earnings

Mar 31, 2025

Yearly revenue growth

118.01%

Earnings per share (EPS): -0.26
Gross Margin: 0%
Net Profit Margin: 0%
Debt/Equity Ratio: 0%

View full report ›

Canadian Market Performance

7 Days: 0.9%
3 Months: 7.4%
1 Year: 19.7%
Year to Date: 7.8%

The Information Technology sector gained 3.5% while the market remained flat over the last week. Meanwhile, the market is actually up 19% over the past year. As for the next few years, earnings are expected to grow by 12% per annum. Market details ›